Literature DB >> 22726085

Standards and monitoring treatment.

T W Barrowcliffe1, A R Hubbard, S Kitchen.   

Abstract

Accuracy and reproducibility of laboratory measurements are important in the diagnosis and treatment of bleeding disorders. This article describes the process of establishment of international standards and some of the problems that have arisen in standardization of these measurements.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22726085     DOI： 10.1111/j.1365-2516.2012.02831.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  6 in total

1.  Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.

Authors:  Ruo-lan Gu; Liang Liu; Liang-zhi Xie; Wen-lin Gai; Si-shuo Cao; Zhi-yun Meng; Hui Gan; Zhuo-na Wu; Jian Li; Ying Zheng; Xiao-xia Zhu; Gui-fang Dou
Journal:  Acta Pharmacol Sin       Date:  2016-01-25       Impact factor: 6.150

Review 2.  BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review.

Authors:  Johnny N Mahlangu; Sanjay P Ahuja; Jerzy Windyga; Nikki Church; Anita Shah; Lawrence Schwartz
Journal:  Ther Adv Hematol       Date:  2018-06-12

3.  A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.

Authors:  Stefan Tiefenbacher; Wan Hui Ong Clausen; Martin Hansen; Rasmus Lützhøft; Mirella Ezban
Journal:  Haemophilia       Date:  2019-07-11       Impact factor: 4.287

Review 4.  Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.

Authors:  Richard A Marlar; Karin Strandberg; Midori Shima; Dorothy M Adcock
Journal:  Eur J Haematol       Date:  2019-11-13       Impact factor: 2.997

5.  Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.

Authors:  J M Sommer; N Moore; B McGuffie-Valentine; S Bardan; Y Buyue; G D Kamphaus; B A Konkle; G F Pierce
Journal:  Haemophilia       Date:  2013-11-22       Impact factor: 4.287

6.  Activity measurements of dalcinonacog alfa.

Authors:  Stella C Williams; Elaine Gray
Journal:  Haemophilia       Date:  2020-03-06       Impact factor: 4.287
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.